Analyst debate weighs
Vertex is drifting moderately lower as a bearish analyst piece questioning its overreliance on cystic fibrosis revenue circulates, offsetting a UBS price target raise and outpacing a mild broad market dip.
Sources: https://seekingalpha.com/article/vertex-stock-still-too-much-emphasis-on-cf-supremacy-i-foresee-rating-downgrade, https://www.investing.com/news
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works